Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis
- PMID: 37080831
- DOI: 10.1016/j.vaccine.2023.04.011
Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis
Abstract
Background: The World Health Organization has recommended a 4-dose schedule of the RTS,S/AS01 (RTS,S) vaccine for children in regions of moderate to high P. falciparum transmission. Faced with limited supply and finite resources, global funders and domestic malaria control programs will need to examine the relative cost-effectiveness of RTS,S and identify target areas for vaccine implementation relative to scale-up of existing interventions.
Methods: Using an individual-based mathematical model of P. falciparum, we modelled the cost-effectiveness of RTS,S across a range of settings in sub-Saharan Africa, incorporating various rainfall patterns, insecticide-treated net (ITN) use, treatment coverage, and parasite prevalence bands. We compare age-based and seasonal RTS,S administration to increasing ITN usage, switching to next generation ITNs in settings experiencing insecticide-resistance, and introduction of seasonal malaria chemoprevention (SMC) in areas of seasonal transmission.
Results: For RTS,S to be the most cost-effective intervention option considered, the maximum cost per dose was less than $9.30 USD in 90.9% of scenarios. Nearly all (89.8%) values at or above $9.30 USD per dose were in settings with 60% established bed net use and / or with established SMC, and 76.3% were in the highest PfPR2-10 band modelled (40%). Addition of RTS,S to strategies involving 60% ITN use, increased ITN usage or a switch to PBO nets, and SMC, if eligible, still led to significant marginal case reductions, with a median of 2,653 (IQR: 1,741 to 3,966) cases averted per 100,000 people annually, and 82,270 (IQR: 54,034 to 123,105) cases averted per 100,000 fully vaccinated children (receiving at least three doses).
Conclusions: Use of RTS,S results in reductions in malaria cases and deaths even when layered upon existing interventions. When comparing relative cost-effectiveness, scale up of ITNs, introduction of SMC, and switching to new technology nets should be prioritized in eligible settings.
Keywords: Malaria; Malaria vaccine; Mathematical modelling; P. falciparum; RTS,S.
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.Lancet. 2016 Jan 23;387(10016):367-375. doi: 10.1016/S0140-6736(15)00725-4. Epub 2015 Nov 6. Lancet. 2016. PMID: 26549466 Free PMC article.
-
Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study.Lancet Glob Health. 2022 Dec;10(12):e1782-e1792. doi: 10.1016/S2214-109X(22)00416-8. Lancet Glob Health. 2022. PMID: 36400084 Clinical Trial.
-
Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.PLoS Med. 2020 Nov 30;17(11):e1003377. doi: 10.1371/journal.pmed.1003377. eCollection 2020 Nov. PLoS Med. 2020. PMID: 33253211 Free PMC article.
-
The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.Mol Biochem Parasitol. 2021 Nov;246:111425. doi: 10.1016/j.molbiopara.2021.111425. Epub 2021 Oct 16. Mol Biochem Parasitol. 2021. PMID: 34666102 Free PMC article. Review.
-
Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.BMJ Glob Health. 2024 Apr 30;9(4):e014719. doi: 10.1136/bmjgh-2023-014719. BMJ Glob Health. 2024. PMID: 38688566 Free PMC article. Review.
Cited by
-
Therapeutic development to accelerate malaria control through intentional intervention layering.Malar J. 2025 Jan 13;24(1):12. doi: 10.1186/s12936-024-05222-4. Malar J. 2025. PMID: 39806410 Free PMC article. Review.
-
Quantifying the potential value of entomological data collection for programmatic decision-making on malaria control in sub-Saharan African settings.Malar J. 2025 Jan 30;24(1):31. doi: 10.1186/s12936-025-05251-7. Malar J. 2025. PMID: 39885514 Free PMC article.
-
How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays.Vaccines (Basel). 2024 May 28;12(6):586. doi: 10.3390/vaccines12060586. Vaccines (Basel). 2024. PMID: 38932315 Free PMC article. Review.
-
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.Cell Rep Med. 2024 Jul 16;5(7):101654. doi: 10.1016/j.xcrm.2024.101654. Cell Rep Med. 2024. PMID: 39019011 Free PMC article.
-
Mapping climate change-driven epidemics.Front Epidemiol. 2025 Jul 29;5:1605058. doi: 10.3389/fepid.2025.1605058. eCollection 2025. Front Epidemiol. 2025. PMID: 40799456 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical